直接口服抗凝药每日一次与每日两次给药方案的依从性与持续性:系统综述
多数结局中OD方案显著优于BID(P < .05),依从性支持OD占53.1%、支持BID仅12.2%;持续性支持OD占67.7%、支持BID占14.9%。结论认为NVAF患者OD方案的依从性和持续性均高于BID方案。
要点
- NVAF患者DOAC每日一次方案的依从性和持续性在多数结局中显著优于每日两次方案。
- 依从性结局中53.1%支持OD、12.2%支持BID;持续性结局中67.7%支持OD、14.9%支持BID。
- 上述结果随时间保持一致,但不同DOAC分子间存在差异。
核心结论
- 在非瓣膜性房颤患者中,每日一次DOAC方案的依从性和持续性均高于每日两次方案。
研究设计与样本
- 系统综述,检索PubMed、Scopus和Cochrane Library,纳入提供OD与BID方案依从性和/或持续性定量比较数据的文章。
- 进行总体结局分析和限制性分析以降低高估风险,并按随访天数和DOAC分子做单变量分析。
主要发现
- 多数结局中OD方案的依从性和持续性显著高于BID方案(P < .05)。
- 依从性结局中53.1%支持OD、12.2%支持BID。
- 持续性结局中67.7%支持OD、14.9%支持BID。
- 结果随时间保持一致,但不同DOAC分子间存在差异。
临床怎么用
- 在NVAF患者选择DOAC时,可将每日一次方案作为提高依从性和持续性的考量因素。
- 需结合具体DOAC分子间的差异进行个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Direct oral anticoagulants (DOACs) are used in patients with non-valvular atrial fibrillation (NVAF) to prevent complications such as embolic events. Poor adherence to DOACs increases the risk of these complications. This manuscript reviews the impact of once-daily (OD) vs twice-daily (BID) dosing regimens on adherence and persistence to the authorized DOACs (dabigatran, rivaroxaban, apixaban and edoxaban) in patients with NVAF, aiming to provide insights into guide clinical decision-making. METHODS: A systematic review was performed. First, a bibliographical search was carried out in PubMed, Scopus and the Cochrane Library. Articles that provided quantitative data comparing adherence and/or persistence associated with OD vs BID regimens of DOACs among patients receiving treatment for NVAF were included. Two analyses of adherence and persistence were conducted, one based on the overall outcomes and another, more restricted, to minimize the risk of overestimating results. Additionally, univariate analyses were conducted based on the number of follow-up days and the DOAC molecule. RESULTS: Thirty-nine studies, involving 976 494 patients, were analysed. The OD regimen demonstrated significantly higher adherence and persistence (P < .05) than the BID regimen in most outcomes. Adherence favoured OD in 53.1% of cases, while only 12.2% favoured BID. Similarly, persistence was higher with the OD regimen in 67.7% of cases compared to 14.9% for the BID regimen. These results remained consistent over time; nevertheless, variations were observed depending on the specific DOAC molecules. CONCLUSION: Adherence and persistence of treatment with DOACs in patients with NVAF were greater for the OD than for the BID regimen.
引用
- Quirós López R, Formiga Pérez F, Beyer-Westendorf J, et al. Adherence and persistence with direct oral anticoagulants by dose regimen: A systematic review. Br J Clin Pharmacol. 2025. PMID: 39957057. doi:10.1002/bcp.70003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。